- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: 💯835.
Displaying page 1 of 2.
EudraCT Number: 2014-003022-40 | Sponsor Protocol Number: UKM14_0008 | Start Date*: 2015-03-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004178-24 | Sponsor Protocol Number: RP-OSV-02-D | Start Date*: 2013-12-27 |
Sponsor Name:Fresenius Medical Care Deutschland GmbH | ||
Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules | ||
Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-018072-33 | Sponsor Protocol Number: UKM08_0057 | Start Date*: 2011-08-01 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Münster | ||||||||||||||||||
Full Title: Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours | ||||||||||||||||||
Medical condition: Intracranial Germ Cell tumours of any histology and intracranial site and dissemination | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) FR (Completed) AT (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001029-84 | Sponsor Protocol Number: AL0702rB | Start Date*: 2007-08-30 | ||||||||||||||||
Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall... | ||||||||||||||||||
Medical condition: ICD classification code: J45.0 and J30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004824-19 | Sponsor Protocol Number: ML21206 | Start Date*: 2008-08-08 |
Sponsor Name:Roche Austria GmbH | ||
Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | ||
Medical condition: Chronic Lymphocytic Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-004616-21 | Sponsor Protocol Number: CFTY720D2415T | Start Date*: 2014-03-13 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous tre... | |||||||||||||
Medical condition: relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001976-12 | Sponsor Protocol Number: FLAG-QUIDA | Start Date*: 2019-09-12 | |||||||||||
Sponsor Name:Fundación Pethema | |||||||||||||
Full Title: A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refract... | |||||||||||||
Medical condition: relapsed/refractory acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004557-24 | Sponsor Protocol Number: UKM17_0056 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel | |||||||||||||
Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002727-25 | Sponsor Protocol Number: UKM12_0017 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma | |||||||||||||
Medical condition: Recurrent glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000381-34 | Sponsor Protocol Number: CL019_168 | Start Date*: 2023-05-30 |
Sponsor Name:ChemoCentryx | ||
Full Title: An Open Label, Randomized, Crossover, Single Dose Bioavailability Study in Healthy Adult Subjects to Evaluate the Pharmacokinetic Profile of an Exploratory Avacopan Pediatric Liquid Formulation Com... | ||
Medical condition: Anti-Neutrophil Cytoplasmic Antibody associated vasculitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-003481-25 | Sponsor Protocol Number: DIMAT-MS | Start Date*: 2015-05-13 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis | |||||||||||||
Medical condition: relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003256-22 | Sponsor Protocol Number: UKM17_0017 | Start Date*: 2018-03-22 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma | |||||||||||||
Medical condition: diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001138-10 | Sponsor Protocol Number: F-FR-00250-105 | Start Date*: 2016-01-06 | |||||||||||
Sponsor Name:Ipsen Pharma SAS | |||||||||||||
Full Title: Efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults. A multicentre, randomised, double-blind, placebo-controlled, parallel groups study | |||||||||||||
Medical condition: Acute diarrhoea in adult | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004539-57 | Sponsor Protocol Number: Dio/01/2013 | Start Date*: 2014-01-30 | ||||||||||||||||
Sponsor Name:ALIO MEDICA Sp. z o.o. | ||||||||||||||||||
Full Title: A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleang... | ||||||||||||||||||
Medical condition: lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008265-36 | Sponsor Protocol Number: KETOP_C_03968 | Start Date*: 2009-05-26 | |||||||||||
Sponsor Name:SANOFI-AVENTIS GROUPE | |||||||||||||
Full Title: “A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) in patients with sore throat” | |||||||||||||
Medical condition: upper respiratory illness : sore throat | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) FR (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007495-20 | Sponsor Protocol Number: ML22056 | Start Date*: 2009-03-30 | |||||||||||
Sponsor Name:Roche Austria GmbH | |||||||||||||
Full Title: A single arm, open-label, multicentre, phase II study to evaluate the efficacy and safety of bevacizumab and trastuzumab combination and sequential capecitabine in patients with HER2-positive local... | |||||||||||||
Medical condition: Male or female patients with locally recurrent or metastatic HER2-positive breast cancer who have relapsed early after adjuvant treatment that included trastuzumab and who have not received prior c... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000695-38 | Sponsor Protocol Number: 2020-000695-38 | Start Date*: 2020-06-12 |
Sponsor Name:Karolinska Universitetssjukhuset | ||
Full Title: Healthy diet rich in potassium containing fruits, vegetables and nuts to chronic kidney disease patients thought the use of sodium zirconium cyclosilicate: A Feasibility Study | ||
Medical condition: Chronic kidney disease, stages 4 and 5 of the disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003088-87 | Sponsor Protocol Number: WWU20_0016 | Start Date*: 2021-11-22 | |||||||||||||||||||||||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster | |||||||||||||||||||||||||||||||||
Full Title: Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery | |||||||||||||||||||||||||||||||||
Medical condition: Cardiac surgical patients at high risk for AKI | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002758-22 | Sponsor Protocol Number: V503-003 | Start Date*: 2012-12-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to ... | |||||||||||||
Medical condition: Prevention of external genital lesions, anal cancers and related precancers, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Not Authorised) SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
